The study of the pathophysiology of malignant glioma and development of treatment strategies

恶性胶质瘤是不可避免的致命，尽管协调一致，跨学科的努力，以改善这些肿瘤患者的预后。恶性胶质瘤的生物学特征是其生长迅速、新生血管形成和向周围脑组织的侵袭。各种各样的分子在这些事件中起着重要的作用。我们研究了恶性胶质瘤的病理生理学，努力开发新的治疗策略，以打击这些恶性肿瘤。我们以前纯化的MCP-1（单核细胞趋化蛋白-1）从胶质瘤细胞，并证实，这种蛋白质参与显着的巨噬细胞侵入胶质瘤组织。因此，我们假设恶性胶质瘤生长的控制可能是可能的，通过调节分子的活动导致恶性胶质瘤的特征。我们随后建立了MCP-1和凝血酶来自胶质瘤细胞参与这些肿瘤的新生血管特征。使用构象表位识别单克隆抗体和相展示文库，我们成功地在MCP-1受体基因的克隆和功能特性，并产生了一个肽，模拟MCP-1和表达拮抗活性。我们还开发了高效的电基因治疗实体肿瘤，并建议我们的可喜的结果将导致对恶性肿瘤的临床适用的治疗策略的发展。

Malignant gliomas are inevitably fatal, despite concerted, interdisciplinary efforts to improve the prognosis of patients with these tumors. The biological characteristics of malignant gliomas are their fast growth, neovascularization, and invasiveness into the surrounding brain. A great variety of molecules play important roles in these events. We studied the pathophysiology of malignant gliomas in Nan effort to develop novel treatment strategies to combat these malignant neoplasms.We previously purified MCP-1 (monocyte chemoattractant protein-1) from glioma cells and confirmed that this protein participates significantly in the invasion of macrophages into glioma tissue. Therefore, we posited that control of malignant glioma growth may be possible via the regulation of molecules whose activities result in the characteristic features of malignant gliomas.We subsequently established that MCP-1 and thrombin derived from glioma cells are involved in the neovascularization characteristic of these tumors. Using a conformation-epitope-recognizing mAb and a phase-display library, we succeeded in the cloning and functional characterization of the MCP-1 receptor gene and produced a peptide that mimics MCP-1 and expresses antagonistic activity. We also developed highly efficient electro-gene therapy for solid tumors arid suggest that our gratifying results will lead to the development of clinically applicable treatment strategies against malignant tumors.